Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Just hours after reports began surfacing June 9 that four of the 17 members of the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) had been terminated, Health and Human Services (HHS) ...

The European Commission is seeking feedback from stakeholders on the oversight of high-risk AI products, one objective of ...

Australia’s Therapeutic Goods Administration initiated court proceedings against Philips Electronics Australia Ltd. over ...

Absent extraordinary circumstances, the Patent Trial and Appeal Board “should never cancel claims it has not determined to be unpatentable as a sanction” for misconduct during a board proceeding, ...

One of the big questions going into the phase I readout for Metsera Inc.’s amylin analogue, MET-233i, was whether findings would support once-monthly dosing for the potential obesity candidate. They ...

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...

The top 10 med-tech stock gainers and losers for the week.

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...